Evaluation of Serum Perlecan and Ischemia-Modified Albumin in Pediatric Patients with Hypertension
Project no. 24013 · Status: Kapanmış (Yayın bekleniyor) · 2023
Summary
<p>Hypertension is a significant risk factor for cardiovascular diseases, which are a major cause of mortality and morbidity worldwide. In childhood hypertension, target organ damage can occur in the kidneys, eyes, and cardiovascular system. Preventing or detecting target organ damage early, closely monitoring the effectiveness of follow-up and treatment, and protecting against cardiovascular diseases and complications that impact adulthood is crucial. Therefore, it is important to detect target organ involvement early and develop treatments accordingly. However, there is no single marker that can be used alone to indicate this before morphological changes appear.</p><p><br></p><p>Perlecan is a heparan sulfate proteoglycan protein found in the extracellular matrix. Increased expression of basal membrane perlecan has been reported to be associated with atherosclerotic lesions in studies on mice and humans. Moreover, mice with perlecan deficiency have shown less atherosclerosis.</p><p><br></p><p>Ischemia-modified albumin is formed by the modification of albumin due to reactive oxygen species generated as a result of ischemia. It has been suggested that ischemia-modified albumin, along with hs-CRP and fibrinogen levels, can help diagnose the risk of developing complications in the early stages of metabolic and cardiovascular diseases in patients with type 2 diabetes mellitus. It has been reported that serum ischemia-modified albumin and perlecan levels in preeclamptic patients show a positive correlation with systolic and diastolic blood pressure. As far as we can find, there has been no clinical study evaluating serum perlecan and ischemia-modified albumin levels, both separately and together, in pediatric patients with hypertension. This study aims to measure serum perlecan and ischemia-modified albumin levels in children diagnosed with hypertension and compare them with a control group. The secondary aim is to evaluate whether there is a relationship with target organ damage. For this purpose, children with hypertension followed by the Pediatric Nephrology Department of Ege University Medical Faculty and healthy controls will be included.</p>